Comparisons were made between the intracellular phosphorylation of 3'-azido-3'-deoxythymidine (AZT) alone and in combination with ganciclovir (GCV) or foscarnet (PFA) in lymphocytes, uninfected fibroblasts and CMV-infected fibroblasts. The effects of AZT and the combinations of AZT with GCV or PFA on cellular dNTP pools were also examined.
Introduction
Infection with cytomegalovirus (CMV) is a common occurrence in patients with decreased cellular immunity causing life-threatening opportunistic disease (Betts, 1982; Schooley, 1990) . Invasive CMV infection of the eyes, lungs, gastro-intestinal tract and liver occur in approximately 90% of patients with acquired immunodeficiency syndrome (AIDS) (Guarda et el., 1984; Moskowitz et el., 1985;  Collaborative DHPG treatment study group 1986; Schooley, 1990) . Of these, 40% may develop lifeor sight-threatening disease related to CMV infection (Jacobson and Mills, 1988a; Gallant et et., 1992; Pertel et sl., 1992) . CMV infection is a relatively late manifestation of AIDS and can be directly related to the reduction of CD4+ lymphocytes and impairment in immunity (Schooley, 1990; Gallant et et., 1992) .
The two drugs currently approved for the treatment of CMV in AIDS patients are ganciclovir (GCV) and foscarnet (PFA). Ganciclovir is a guanosine nucleoside analogue, and must be metabolized to its triphosphate form in CMV-infected cells by viral and cellular enzymes in order to inhibit the CMV DNA polymerase enzyme (Littler et a/., 1992; Sullivan et el., 1992) . PFA is a pyrophosphate analogue Which directly inhibits the DNA polymerase enzyme from CMV and the reverse transcriptase enzyme of the human immunodeficiency virus (HIV) (Helgstrand et aI., 1978; Oberg 1983; Fletcher et el., 1994; Wagstaff and Bryson, 1994) . Both of these drugs are effective antiviral agents and have been used as sole (Collaborative DHPG treatment study group, 1986; Masur et el., 1986; Harris and Mathalone, 1987; Laskin et et., 1987; Palestine et el., 1991; Jacobson et et., 1993; Wagstaff and Bryson, 1994) , alternating (Aweeka et el., 1989; Jacobson et et., 1991; Jacobson et et., 1994a) and combination (Jacobson et el., 1994b) therapies for the treatment of CMV infection in AIDS patients.
An important consideration in the use of anti-CMV drugs for AIDS patients is the anti-HIV therapy they may be receiving. The nucleoside analogue, 3'-azido-3'deoxythymidine (AZT), is frequently used for the treatment of HIV. The combination of GCV and AZT shows synergistic cellular toxicity in studies in vitro, and GCV also antagonizes the anti-HIV activity of AZT (Prichard et el., 1991; Medina et a/., 1992; Cox et el., 1993) . Furthermore, administration of both GCV and AZT to CMV-infected AIDS patients in clinical trials has revealed the increased toxicity of this combination (Jacobson et ei., 1988b; Hochster et al., 1990; Millar et el., 1990; Studies of ocular complications of AIDS research group, 1992) . Conversely, the combination of PFA and AZT synergistically inhibits HIV replication in vitro (Eriksson and Schinazi, 1989; Koshida et el., 1989; Kong et et., 1991) . A clinical trial comparing GCV and PFA for treatment of CMV retinitis in AIDS patients showed PFA to have a survival benefit over GCV, even after correction for the length of anti-retroviral therapy (Studies of ocular complications of AIDS research group, 1992). However, the biochemical mechanisms responsible for the antagonistic interaction of GCV with AZT, or the synergistic interaction of PFA with AZT, are unknown.
Besides its importance as an opportunistic infection in AIDS patients, there is also evidence that certain cells may be infected with both CMV and HIV (Ho et a/., 1991; Jault et el., 1994) . Both enhancement and suppression of HIV replication by CMV have been reported (Jacobson and Mills, 1988a; Schooley 1990; Ho et el., 1991; Koval et a/., 1991; Jault et al., 1994) . However, the effects of CMV infection upon the anti-HIV activity of AZT are not known. For instance, it has not been shown whether AZT can effectively inhibit HIV replication in such CMV and HIV coinfected cells.
AZT is a nucleoside analogue and must be metabolized intracellularly to the active triphosphate form by cellular enzymes of the thymidine salvage pathway (Furman et el., 1986) . Alterations in the activity of the cellular phosphorylating enzymes, and/or the levels of competing natural nucleotide pools, affect the metabolism and antiviral activity of AZT, and could explain the antagonistic effect of GCV upon the anti-HIV activity of AZT.
In the present study, comparisons were made between the intracellular metabolism of AZT alone and in combination with GCV or PFA in human CD4+ Iymphoblastoid (CEM) cells and CMV-infected and uninfected human lung fibroblast (HL) cells. The effects of AZT and the cornbinations on natural deoxynucleotide pools (dNTPs) were also investigated in each cell type. Table 1 shows the phosphorylation of AZT in CEM cells when incubated alone, in combination with PFA, or in combination with two different concentrations of GCV. Large amounts of AZT monophosphate, representing greater than 90% of the total AZT phosphorylated metabolites, were formed in CEM cells incubated with AZT alone or with the different drug combinations. The levels of AZT di-and triphosphate derivatives were approximately the same and represented between 1.3-3.0% of the total AZT metabolites. The amount of AZT TP formed in all the drug combinations with PFA or GCV was similar to that formed when cells were incubated with AZT alone.
Results

Phosphorylation of AZT alone or in combination with PFA or GGV in GEM cells
Effect of drugs on cellular dNTP pools in GEM cells
The intracellular dNTP pools of CEM cells incubated with AZT, AZT and PFA, or two different combinations of AZT and GCV, were measured by ion exchange HPLC and are shown in Table 2 . No appreciable changes were found in the levels of dNTP pools from cells treated with AZT or combinations of AZT with either PFA or GCV. Table 3 shows the phosphorylation of AZT in CMVinfected and uninfected fibroblasts in the presence or absence of GCV. AZT was phosphorylated to a lower extent in uninfected fibroblasts compared to lymphocytes. However, AZT DP and -TP added together constituted more than 20% of the total AZT metabolites formed in fibroblasts, compared to less than 4% in lymphocytes. The ratio of AZT MP:AZT TP in lymphocytes was about 50:1 whereas in fibroblasts it was close to 7:1. There was about a twenty-fold increase in the levels of mono-, diand triphosphate derivatives of AZT formed in CMVinfected fibroblasts compared to uninfected cells. However, the overall percentage of each AZT metabolite remained similar in CMV-infected cells. GCV at 10 11M had no effect on the phosphorylation of AZT in uninfected fibroblasts. Both the absolute and the relative proportions of the different phosphorylated species remained similar. However, in CMV-infected fibroblasts, 10 11M GCV caused a marked reduction in the amount of AZT MP and AZT DP formed. A seven-fold decrease in the amount of AZT TP formed compared to CMV-infected cells incubated with AZT alone was also seen. The pattern of phosphorylation also changed: the percentage of the total products existing as AZT MP increased, whereas there was a two to three-fold decrease in the percent of the total products existing as AZT DP and AZTTP.
Phosphorylation of AZT alone or in combination with GCV in CMV-infected or uninfected HL cells
Effects of drugs on cellular dNTP pools in CMV-infected and uninfected fibroblasts
The intracellular dNTP levels of CMV-infected and uninfected fibroblasts incubated with AZT or a combination of AZT and GCV are shown in Table4. Uninfected fibroblasts had low levels of all dNTPs, especially purine dNTPs which were undetectable. Infection of fibroblasts with CMV dramatically increased the levels of all dNTPs. In uninfected cells, AZT caused an 80% reduction in dCTP compared to untreated cells, but the levels of the other dNTPs were similar. CMV-infected cells treated with AZT had lower levels of all dNTPs than untreated infected cells, but they were still higher than those seen in uninfected untreated cells. Likewise, CMV-infected cells treated with AZT and GCV had lower levels of dNTPs than untreated infected cells, but levels were higher than those in CMV-infected cells treated with AZT alone, except for dGTP.
Discussion
In lymphocytes, in agreement with previous studies (Furman et el., 1986; T6rnevik et el., 1991) , AZT accumulated mainly as the monophosphate, with the triphosphate representing only 1-3% of the total AZT metabolites. Neither PFAat 100l1M nor GCV at 1 or 10l1M had any effect on AZT phosphorylation. There was no effect on the levels of Table 3 . Phosphorylation of AZT in CEM cells and CMV infected and uninfected HL cells in the presence or absence of GCV. CMV infected or uninfected HL cells were incubated with 11lM3[H]-AZT alone or in combination with 10llM GCV. The deoxynucleotides were extracted and separated by ion exchange HPLC. 0.5 min fractions were collected and the phosphorylation profile of each AZT metabolite was determined and quantified by scintillation counting. Results are expressed as the mean ± standard deviation of three values.
Drugs
Cell cellular dNTP pools, in agreement with recent observations (Gao et el., 1993; Palmer and Cox, 1994b; Palmer and Cox, 1995) .
AZT was phosphorylated to a much lower extent in uninfected fibroblasts than in lymphocytes, but the amount of AZT TP formed represented a greater percent of the total AZT metabolites. The infection of fibroblasts with CMV increased the phosphorylation of AZT with an increase in all AZT metabolites. However, in percentage terms the proportion of the different phosphorylated metabolites remained similar. It has previously been shown that CMV infection increases cellular thymidine kinase activity, and CMV-infected fibroblasts exhibit an increase in dTIP pools (Estes and Huang, 1977; Wachsman et ei., 1995) . In fact dramatic increases were seen in all dNTPs upon CMV infection when compared to uninfected cells, in agreement with previous data (Freitas et et., 1985) . This increase in thymidine kinase activity may explain the enhanced phosphorylation of AZT in CMV-infected fibroblast cells.
The effects of GCV on AZT phosphorylation in fibroblast cells were also examined. GCV had no effect on AZT phosphorylation in uninfected fibroblasts. However, in CMV-infected fibroblasts the phosphorylation of AZT was reduced in the presence of GCV, although it was still above the level seen in uninfected fibroblast cells. This reduction in AZT phosphorylation was not accompanied by a reduction in dTIP. In fact, dTIP pools were higher in infected cells treated with AZT and GCV than in those treated with AZT alone. The reduction in AZT TP formed in the presence of GCV together with the expansion of the dTIP pool will have a noticeable effect on the AZT TP/ dTIP ratio, which is a decisive factor for the antiviral activity of AZT. GCV did not have this effect on AZT phosphorylation in uninfected lymphocytes or fibroblasts. This might indicate that a phosphorylated metabolite of GCV interferes with the phosphorylation of AZT since GCV is preferentially phosphorylated in CMV-infected cells.
The pattern of AZT phosphorylation also changed in the presence of GCV in CMV-infected fibroblasts. An increase in the proportion of AZT monophosphate and decreases in the proportion of the di-and triphosphate derivatives were seen. Therefore, the presence of GCV caused both quantitative and qualitative changes in AZT phosphorylation in CMV-infected fibroblasts. This, together with the lack of effect of GCV in uninfected cells (where GCV is not metabolized), and the known inefficiency of the AZT MP to AZT DP conversion, (Furman et al., 1986) indicates that a metabolite of GCV interferes with the phosphorylation of AZT between the monophosphate and diphosphate derivatives, thus causing a higher percentage of monophosphate to be accumulated.
In summary, the phosphorylation of AZT in uninfected lymphocytes or fibroblasts was unchanged by the pres-AZT in combination with GCV or PFA 17 ence of GCV or PFA. CMV infection of fibroblasts enhanced AZT phosphorylation and increased cellular dNTP pools. The presence of GCV caused a specific quantitative and qualitative reduction in AZT phosphorylation in CMV-infected fibroblast cells without an accompanying decrease in dTIP.
These results could be of importance for the use of GCV in AZT -treated patients. There is evidence that cells may be co-infected with CMV and HIV in vitro and in vivo, and that CMV may be a possible cofactor for HIV progression (Davis et el., 1987; Ho et el., 1991) . Combination treatment with GCV and AZT might reduce the phosphorylation, and therefore the anti-HIV activity, of AZT in cells co-infected with both CMV and HIV. Furthermore, these findings may shed light on the antagonistic effects of GCV on the anti-HIV activity of AZT and on the results of the SaCA study where PFA was found to give a survival advantage over GCV for the treatment of CMV in AIDS patients (Studies of ocular complications of AIDS research group, 1992).
Materials and Experimental Procedures
Chemicals
Pure nucleotides were purchased from Sigma Chemical Co. (St Louis, MO, USA). 3'-azido 3'-deoxythymidine, (methyl-3[H]) (14Ci rnrnol", 99.9% pure) was purchasedfrom Moravek Biochemicals Inc. (Brea, CA, USA). Ganciclovir was purchased from Syntex Nordica (Sodertalje, Sweden). Foscarnet was a kind gift from Astra Arcus (S6dertalje, Sweden).
Cell culture
CEM cells (a human CD4+ Iymphoblastoid cell line) were grown in RMPI 1640 medium containing 10% heat-inactivated fetal calf serum, penicillin, streptomycin, and pyruvate at 37 "O in a humidified atmosphere of 5% CO 2 in air. Human embryonic lung (HL) fibroblast cells were grown in 2 I plastic roller flasks in Eagles mediumcontaining 7.5% heat-inactivated fetal calf serum, penicillin and streptomycin at 3rC in a humidified atmosphereof 5% CO 2 in air.
Virus infection
Confluent monolayers of HL fibroblasts in roller flasks were inoculatedwith approximately 0.005 PFU per cell of CMV laboratory strain AD 169 and the virus was allowed to adsorb for 60 min at 37 cC.The virus inoculumwas then replaced with 150 ml of fresh Eagles medium. The end of virus adsorption was taken as time zero for virus infection.
AZT metabolites and intracellular dNTP levels in CEM cells
For the measurement of AZT metabolites and intracellular dNTP pools, CEM cells (6-8 x10 5 rnr") were incubated with clinically relevant concentrations of AZT alone, AZT and PFA in combination or AZT and GCV in two different combinations: After incubation at 37 DC for 20 h no drug toxicity was found when cells were counted and their viability assessed by the trypan blue exclusion method. The cells were then harvested by centrifugation at 1000 g for 10 min and extracted with 12% cold trichloroacetic acid (TCA). The cells were incubated on ice for 10 min and the precipitated cellular proteins were removed by centrifugation at 1000 g for 10 min. The acidic supernatant was then neutralized by the amine freon method (Khym, 1975) . This method of extracting nucleotides has been shown to give excellent recoveries (Harmenberg et al., 1990) .
AZT metabolites and intracellular dNTP levels in fibroblasts Uninfected cells
For the measurement of AZT metabolites and intracellular dNTP pools in uninfected cells, uninfected HL fibroblast cells were seeded into rollers at 1-2 x10 7 cells per roller. Drugs were added at the peak of cell growth, when TK expression is at a maximum (48 h after seeding; Estes and Huang, 1977) . 1IlM 3[H]-AZT (specific activity 2200000 dpm nrnol") or a twodrug combination of 11lM 3[H]-AZT (specific activity 2200000 dpm nrnor") and 10llM GCV was added and cells harvested after 20 h incubation with the drug(s).
CMV·infected cells
For CMV-infected cells, HL fibroblasts (2-3 x10 7 cells per roller) were infected with CMV at approximately 0.005 PFU per cell. As for uninfected cells, drugs were added at the peak of TK expression (30h p.i.; Estes and Huang, 1977) . 11lM 3[H]· AZT (specific activity 1100000 dpm nrnol") or a two-druq combination of 1IlM 3[H]-AZT (specific activity 1100000 dpm nrnor") and 10llM GCV was added and cells harvested after 20 h incubation with the drug(s).
Uninfected and CMV·infected cells were then harvested by trypsinization. At harvesting, cells were counted and their viability assessed by the trypan blue exclusion method. Viability was 95%. CMV-induced cytopathic effect (CPE) was measured by microscopic examination, and was similar in all CMVinfected cells, including cells treated with AZT or with AZT and GCV. Nucleotides were extracted with 12% TCA as described above.
HPLC analysis
Prior to analysis by high-performance liquid chromatography (HPLC) the ribonucleotides in each sample were degraded by periodate oxidation (Tanaka et al., 1984; Palmer and Cox, 1994a) . After periodate oxidation, all samples were spun at 2000 g for 20 min in a refrigerated centrifuge. Depending on the sample size and the specific activity of AZT, a 200-400 III volume of each sample was injected onto the HPLC. All HPLC analyses were done on a chromatograph from Gilson Medical Electronics Inc. (Middleton, WI, USA) equipped with a dual wavelength spectrophotometer programmed to measure absorbance at 254 and 280 nm. All integration was performed on a Macintosh Classic II computer using RAININ Dynamax HPLC method manager software. Nucleotides were separated on a strong anion exchange column (Partisil 10 SAX, 250 x 4.6 mm J.D.; Whatman, Clifton, NJ, USA) using a phosphate buffer gradient elution (Palmer and Cox, 1994a) . The two buffers used were 0.02 M potassium phosphate (pH 3.5, buffer A) and 0.80 M potassium phosphate (pH 3.5, buffer B). The gradient was completed in four steps.
Step 1 was 100% buffer A for 5 min, Step 2 was a 30 min linear increase in buffer B to 100%.
Step 3 was a constant isocratic 20 min delivery of 100% buffer B. In Step 4, buffer B was decreased to 0% in 10 min. A constant flow of 1.3 ml rnln" was used throughout. During the gradient, thirty second fractions were collected to which 10 ml of scintillation fluid was added and radioactivity determined in a Beckman LS 1801 scintillation counter.
Peaks were identified by retention time on the chromatograph, ratio of absorbance at 254 nm to that at 280 nm, and comparison with known standards. Recoveries were calculated by peak area comparisons of injected samples to those of pure dNTP standards with known concentrations.
